|
GB8504099D0
(en)
|
1985-02-18 |
1985-03-20 |
Wellcome Found |
Physiologically active substances
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
GB8610551D0
(en)
|
1986-04-30 |
1986-06-04 |
Hoffmann La Roche |
Polypeptide & protein derivatives
|
|
JPH0665280B2
(ja)
|
1987-03-04 |
1994-08-24 |
味の素株式会社 |
タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
|
|
EP0355460B1
(en)
|
1988-08-24 |
2000-12-27 |
American Cyanamid Company |
Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
|
|
US5534617A
(en)
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
|
EP0397834B1
(en)
|
1988-10-28 |
2000-02-02 |
Genentech, Inc. |
Method for identifying active domains and amino acid residues in polypeptides and hormone variants
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
ATE193541T1
(de)
|
1989-03-20 |
2000-06-15 |
Gen Hospital Corp |
Insulinotropes hormon
|
|
US5101018A
(en)
|
1989-06-12 |
1992-03-31 |
International Minerals & Chemical Corp. |
Method for recovering recombinant proteins
|
|
DE3930696A1
(de)
|
1989-09-14 |
1991-03-28 |
Hoechst Ag |
Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
ATE164852T1
(de)
|
1990-01-24 |
1998-04-15 |
Douglas I Buckley |
Glp-1-analoga verwendbar in der diabetesbehandlung
|
|
US5951972A
(en)
|
1990-05-04 |
1999-09-14 |
American Cyanamid Company |
Stabilization of somatotropins and other proteins by modification of cysteine residues
|
|
JP2849773B2
(ja)
|
1990-08-27 |
1999-01-27 |
天野製薬株式会社 |
ストレプトミセス属由来のトランスグルタミナーゼの製造法
|
|
DK220890D0
(da)
|
1990-09-14 |
1990-09-14 |
Ole Buchardt |
Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
|
|
CA2095633C
(en)
|
1990-12-03 |
2003-02-04 |
Lisa J. Garrard |
Enrichment method for variant proteins with altered binding properties
|
|
JP3267293B2
(ja)
*
|
1990-12-03 |
2002-03-18 |
ジェネンテク，インコーポレイテッド |
改変された結合性を有する変異タンパク質の豊富化法
|
|
IT1251895B
(it)
|
1991-09-27 |
1995-05-26 |
Eniricerche Spa |
Mutanti dell'ormone della crescita umano e loro impiego
|
|
DE69333718T2
(de)
|
1992-01-14 |
2005-12-01 |
Ajinomoto Co., Inc. |
Gen, das für eine Fisch-Transglutaminase kodiert
|
|
DK0955062T3
(da)
|
1992-07-31 |
2007-09-17 |
Genentech Inc |
Vandig formulering indeholdende humant væksthormon
|
|
ZA936811B
(en)
|
1992-10-28 |
1995-03-15 |
Upjohn Co |
Somatotropin modifications
|
|
US5359030A
(en)
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
|
US5736356A
(en)
|
1994-01-28 |
1998-04-07 |
Ajinomoto Co., Inc. |
Transglutaminase originating from Crassostrea gigas
|
|
NZ291414A
(en)
|
1994-08-26 |
1998-05-27 |
Novo Nordisk As |
Microbial transglutaminases and methods of production using fungi and dna constructs
|
|
EP0785276A4
(en)
|
1994-09-29 |
2002-01-09 |
Ajinomoto Kk |
MODIFICATION OF A PEPTIDE AND A PROTEIN
|
|
DE4437604A1
(de)
|
1994-10-21 |
1996-04-25 |
Basf Ag |
Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
|
|
CA2208730A1
(en)
|
1995-01-19 |
1996-07-25 |
Novo Nordisk A/S |
Transglutaminases from oomycetes
|
|
JP3669390B2
(ja)
|
1995-02-09 |
2005-07-06 |
味の素株式会社 |
バチルス属細菌由来のトランスグルタミナーゼ
|
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
DK0851925T3
(da)
|
1995-09-21 |
2005-11-28 |
Genentech Inc |
Humane Væksthormonvarianter
|
|
US20020077461A1
(en)
|
1996-04-24 |
2002-06-20 |
Soren Bjorn |
Pharmaceutical formulation
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
IL128332A0
(en)
|
1996-08-30 |
2000-01-31 |
Novo Nordisk As |
GLP-1 derivatives
|
|
EP0929576A1
(en)
|
1996-08-30 |
1999-07-21 |
Novo Nordisk A/S |
Glp-2 derivatives
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
CN1231675A
(zh)
|
1996-09-26 |
1999-10-13 |
味之素株式会社 |
修饰的生理活性蛋白及含有该蛋白的药物组合物
|
|
US5985627A
(en)
|
1997-02-28 |
1999-11-16 |
Carlsberg Laboratory |
Modified carboxypeptidase
|
|
JPH1156378A
(ja)
*
|
1997-06-11 |
1999-03-02 |
Nippon Chem Res Kk |
変異型ヒト成長ホルモンとその用途
|
|
ES2332931T3
(es)
|
1997-06-25 |
2010-02-15 |
Merck Serono Sa |
Analogos de hormonas glicoproteinicas entrelazadas por disulfuro, su preparacion y uso.
|
|
ES2297889T3
(es)
|
1997-07-14 |
2008-05-01 |
Bolder Biotechnology, Inc. |
Derivados de hormona de crecimiento y proteinas relacionadas.
|
|
JPH1192499A
(ja)
*
|
1997-09-22 |
1999-04-06 |
Sumitomo Pharmaceut Co Ltd |
ヒト成長ホルモン変異体
|
|
US6136536A
(en)
|
1997-10-29 |
2000-10-24 |
Genetics Institute, Inc. |
Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
|
|
EP1061946B1
(en)
|
1998-02-27 |
2004-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
|
|
JP2002506792A
(ja)
|
1998-02-27 |
2002-03-05 |
ノボ ノルディスク アクティーゼルスカブ |
Ｎ末端修飾ｇｌｐ−１誘導体
|
|
EP1056774A1
(en)
|
1998-02-27 |
2000-12-06 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
|
EP1060192A2
(en)
|
1998-02-27 |
2000-12-20 |
Novo Nordisk A/S |
Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
|
|
JP2003522099A
(ja)
|
1998-02-27 |
2003-07-22 |
ノボ ノルディスク アクティーゼルスカブ |
遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
|
|
US6656922B2
(en)
|
1998-05-28 |
2003-12-02 |
Mediplex Corporation, Korea |
Oral delivery of macromolecules
|
|
US6358705B1
(en)
|
1998-07-16 |
2002-03-19 |
Novo Nordisk A/S |
Method of making proteins in transformed yeast cells
|
|
CZ295044B6
(cs)
|
1998-12-07 |
2005-05-18 |
Societe De Conseils De Recherches Et D'application |
Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
|
|
BR0010750A
(pt)
|
1999-05-17 |
2002-02-26 |
Conjuchem Inc |
Peptìdeos insulinotrópicos de longa duração
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
EP1198565A1
(en)
|
1999-07-07 |
2002-04-24 |
Maxygen Aps |
A method for preparing modified polypeptides
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
GB2355009A
(en)
|
1999-07-30 |
2001-04-11 |
Univ Glasgow |
Peptides conjugated to bile acids/salts
|
|
US20040001827A1
(en)
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
|
WO2001051071A2
(en)
|
2000-01-11 |
2001-07-19 |
Novo Nordisk A/S |
Transepithelial delivery of glp-1 derivatives
|
|
CA2739933A1
(en)
|
2000-02-11 |
2001-08-16 |
Bayer Healthcare Llc |
Factor vii or viia-like molecules
|
|
EP2213743A1
(en)
|
2000-04-12 |
2010-08-04 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
IL152804A0
(en)
*
|
2000-05-16 |
2003-06-24 |
Bolder Biotechnology Inc |
Methods for refolding proteins containing free cysteine residues
|
|
US20020142964A1
(en)
|
2000-11-02 |
2002-10-03 |
Nissen Torben Lauesgaard |
Single-chain polypeptides
|
|
IL155812A0
(en)
|
2000-12-07 |
2003-12-23 |
Lilly Co Eli |
Glp-1 fusion proteins
|
|
AU2002219021A1
(en)
*
|
2001-01-11 |
2002-07-24 |
Maxygen Aps |
Variant growth hormone molecules conjugated with macromolecular compounds
|
|
US20060183197A1
(en)
|
2001-01-11 |
2006-08-17 |
Andersen Kim V |
Variant growth hormone molecules conjugated with macromolecules compounds
|
|
FR2819810B1
(fr)
|
2001-01-23 |
2004-05-28 |
Pf Medicament |
Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
|
|
US6858580B2
(en)
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
|
ES2331909T3
(es)
*
|
2001-06-14 |
2010-01-20 |
The Scripps Research Institute |
Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
|
|
WO2003002136A2
(en)
|
2001-06-28 |
2003-01-09 |
Novo Nordisk A/S |
Stable formulation of modified glp-1
|
|
EP1423136A4
(en)
|
2001-08-10 |
2007-07-25 |
Epix Pharm Inc |
POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULAR HALF TIME
|
|
AR036711A1
(es)
|
2001-10-05 |
2004-09-29 |
Bayer Corp |
Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
|
|
EP1444262A2
(en)
|
2001-11-12 |
2004-08-11 |
University of Wales College of Medicine |
Growth hormone variations in humans and their uses
|
|
WO2003044056A2
(en)
|
2001-11-20 |
2003-05-30 |
Pharmacia Corporation |
Chemically-modified human growth hormone conjugates
|
|
JP2003199569A
(ja)
|
2001-12-17 |
2003-07-15 |
Food Industry Research & Development Inst |
ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
|
|
FR2836382B1
(fr)
|
2002-02-28 |
2004-08-13 |
Biomerieux Sa |
Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic
|
|
AU2003278807A1
(en)
|
2002-03-01 |
2004-08-13 |
Bracco International B.V. |
Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
|
|
CA2480858A1
(en)
|
2002-04-10 |
2003-10-23 |
Eli Lilly And Company |
Treatment of gastroparesis
|
|
WO2003093465A1
(en)
|
2002-04-30 |
2003-11-13 |
Maxygen Holdings Ltd. |
FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
|
|
DE60332358D1
(de)
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
|
DE602004025205D1
(de)
|
2003-02-19 |
2010-03-11 |
Ipsen Pharma |
Glp-1-analoga
|
|
BRPI0409976A
(pt)
|
2003-05-09 |
2006-05-09 |
Novo Nordisk As |
composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
|
|
WO2005014049A2
(en)
|
2003-08-08 |
2005-02-17 |
Novo Nordisk A/S |
Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
|
|
CN100444898C
(zh)
|
2003-09-19 |
2008-12-24 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
|
EP1667724A2
(en)
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
RU2401276C2
(ru)
|
2003-09-19 |
2010-10-10 |
Ново Нордиск А/С |
Производные глюкагон-подобного пептида-1 (glp-1)
|
|
BR122019021416A2
(https=)
|
2003-09-19 |
2019-12-21 |
|
|
|
JP2008502301A
(ja)
|
2003-10-10 |
2008-01-31 |
ノボ ノルディスク アクティーゼルスカブ |
ペプチドの抱合
|
|
ATE461217T1
(de)
|
2003-12-18 |
2010-04-15 |
Novo Nordisk As |
Glp-1-verbindungen
|
|
EP1696962A2
(en)
|
2003-12-18 |
2006-09-06 |
Novo Nordisk A/S |
Novel glp-1 analogues linked to albumin-like agents
|
|
ES2642214T3
(es)
|
2004-01-21 |
2017-11-15 |
Novo Nordisk Health Care Ag |
Conjugación de péptidos mediante transglutaminasa
|
|
BRPI0507169A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
|
BRPI0508798A
(pt)
|
2004-04-07 |
2007-09-04 |
Ares Trading Sa |
formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento
|
|
US7906137B2
(en)
|
2004-05-21 |
2011-03-15 |
Mediplex Corporation, Korea |
Delivery agents for enhancing mucosal absorption of therapeutic agents
|
|
CA2572770A1
(en)
|
2004-07-08 |
2006-01-19 |
Novo-Nordisk A/S |
Polypeptide protracting tags comprising a tetrazole moiety
|
|
US20090176967A1
(en)
|
2004-08-02 |
2009-07-09 |
Novo Nordisk Healthcare A/G |
Conjugation of FVII
|
|
WO2006037810A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
|
CN103520735B
(zh)
|
2004-12-22 |
2015-11-25 |
Ambrx公司 |
包含非天然编码的氨基酸的人生长激素配方
|
|
US8603972B2
(en)
|
2005-03-18 |
2013-12-10 |
Novo Nordisk A/S |
Extended GLP-1 compounds
|
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
EP1863537A2
(en)
|
2005-03-18 |
2007-12-12 |
Novo Nordisk A/S |
Dimeric peptide agonists of the glp-1 receptor
|
|
ES2553160T3
(es)
|
2005-06-17 |
2015-12-04 |
Novo Nordisk Health Care Ag |
Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
|
|
US20090117640A1
(en)
|
2005-08-18 |
2009-05-07 |
Novo Nordisk Health Care Ag |
Transglutaminase Variants with Improved Specificity
|
|
US8293708B2
(en)
|
2005-08-30 |
2012-10-23 |
Novo Nordisk Health Care A/G |
Liquid formulations N-terminal serine of pegylated growth hormone
|
|
CN1939534B
(zh)
|
2005-09-27 |
2010-12-01 |
长春金赛药业股份有限公司 |
含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
|
|
AU2007215566A1
(en)
*
|
2006-01-19 |
2007-08-23 |
Ambrx, Inc. |
Non-natural amino acid polypeptides having modulated immunogenicity
|
|
JP5486809B2
(ja)
|
2006-02-14 |
2014-05-07 |
ノボ ノルディスク ヘルス ケア アーゲー |
Ｃ末端におけるポリペプチドの結合
|
|
BRPI0713963A2
(pt)
|
2006-07-07 |
2012-11-27 |
Novo Nordisk Healthcare Ag |
conjugados de proteìna e métodos para sua preparação
|
|
ES2745411T3
(es)
|
2006-07-27 |
2020-03-02 |
Wang Nai Fang |
Compuestos y composiciones de arilsulfanilo para administración de agentes activos
|
|
WO2008020075A1
(en)
|
2006-08-18 |
2008-02-21 |
Novo Nordisk Health Care Ag |
Transglutaminase variants with improved specificity
|
|
BRPI0716261A2
(pt)
|
2006-08-31 |
2013-08-06 |
Novartis Ag |
composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
|
|
US20080095837A1
(en)
|
2006-08-31 |
2008-04-24 |
Emisphere Technologies, Inc. |
Human growth hormone formulations
|
|
US8383852B2
(en)
|
2007-02-16 |
2013-02-26 |
Emisphere Technologies, Inc. |
Compounds having a cyclic moiety and compositions for delivering active agents
|
|
WO2008112836A2
(en)
|
2007-03-15 |
2008-09-18 |
Novartis Ag |
Pharmaceutical composition comprising human growth hormon
|
|
WO2009030771A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
MX2011000847A
(es)
|
2008-08-06 |
2011-02-25 |
Novo Nordisk Healthcare Ag |
Proteinas conjugadas con eficacia prolongada in vivo.
|
|
WO2010029107A1
(en)
|
2008-09-09 |
2010-03-18 |
Novo Nordisk Health Care Ag |
Growth hormone conjugate with increased stability
|
|
ES2561208T3
(es)
|
2008-09-12 |
2016-02-25 |
Novo Nordisk A/S |
Método de acilación de un péptido o una proteína
|
|
MX2011007736A
(es)
|
2009-01-22 |
2011-09-06 |
Novo Nordisk Healthcare Ag |
Compuestos de hormona del crecimiento estables.
|
|
ES2401965T3
(es)
|
2009-02-19 |
2013-04-25 |
Novo Nordisk A/S |
Modificación de Factor VIII
|
|
WO2011015649A1
(en)
|
2009-08-06 |
2011-02-10 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
|
MX338357B
(es)
|
2010-01-22 |
2016-04-13 |
Novo Nordisk Healthcare Ag |
Compuestos estables de la hormona de crecimiento.
|
|
RS59459B1
(sr)
|
2010-01-22 |
2019-11-29 |
Novo Nordisk Healthcare Ag |
Hormoni rasta sa produženom in-vivo efikasnošću
|
|
ES2582590T3
(es)
|
2010-02-16 |
2016-09-13 |
Novo Nordisk A/S |
Método de purificación
|